In addition, our studies suggest that FGF2 exerts its effects in human ovarian cancer cells via the activation of the PI3K/Akt/mTOR and MAPK/ERK signaling pathways and the subsequent increased expression of Slug and ZEB1. Here, MAPK1 is linked to ovarian carcinoma.